Multidrug-resistant tuberculosis in Port-au-Prince, Haiti.

Oksana Ocheretina, Willy Morose, Marie Gauthier, Patrice Joseph, Richard D’Meza, Vincent E Escuyer, Nalin Rastogi, Guy Vernet, Jean W Pape, Daniel W Fitzgerald

To cite this version:

HAL Id: pasteur-00708382
https://hal-riip.archives-ouvertes.fr/pasteur-00708382
Submitted on 14 Jun 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Multidrug-resistant tuberculosis in Port-au-Prince, Haiti

Oksana Ocheretina,1 Willy Morose,2 Marie Gauthier,3 Patrice Joseph,2 Richard D’Meza,4 Vincent E. Escuyer,5 Nalin Rastogi,6 Guy Vernet,3 Jean W. Pape,2 and Daniel W. Fitzgerald1


ABSTRACT Objective. To determine the prevalence of multidrug-resistant tuberculosis (MDR-TB) among patients with new smear-positive pulmonary TB in Port-au-Prince, Haiti. Methods. Sputum samples were cultured from 1 006 patients newly diagnosed with TB in 2008. The core region of the rpoB gene that is associated with resistance to rifampin was sequenced. All isolates with rpoB mutations were sent to the New York State reference laboratory for conventional drug susceptibility testing (DST). All isolates were also tested with the GenoType MTBDRplus line-probe assay. Results. Mycobacterium tuberculosis was isolated from 906 patients. Twenty-six (2.9%) of the isolates had missense mutations or deletions in rpoB and were resistant to rifampin by DST. All 26 were also resistant to isoniazid and classified as MDR-TB. Forty-six control isolates without rpoB mutations were found to be rifampin sensitive by DST. The GenoType MTBDRplus line-probe assay correctly identified 26 MDR-TB strains. It misclassified one pansusceptible isolate as rifampin resistant. Conclusions. This study shows an MDR-TB prevalence of 2.9% in newly diagnosed TB patients in Haiti and suggests that rpoB sequencing and hybridization assays are good screening tools for early detection of MDR-TB.

Key words Tuberculosis, multidrug resistant; cross-sectional studies; Haiti.
patient newly diagnosed with TB (7). In a 1991 study of recent migrants from Haiti to Cuba, monoresistance to isoniazid was found in 22% of TB patients but MDR-TB was not found (8). However, a study in 2002 of patients presenting to an HIV/AIDS center in Port-au-Prince, Haiti, with new onset tuberculosis found a rate of primary MDR-TB of 6% (9). The 2002 study was small and limited to a single HIV testing center but suggested an increase in MDR-TB.

In 2010, the World Health Organization (WHO) estimated that 3.4% of new TB cases globally and 2.1% of new cases in the Americas were MDR-TB (1). In the Caribbean, rates of MDR-TB range from < 1.0% of new cases in Cuba to 6.6% in the Dominican Republic (10, 11). Because of limited data on drug resistance, the WHO has not provided a definitive assessment of trends in MDR-TB over time globally or in the Americas. It is hoped that with recent advances in molecular techniques, more drug-resistance data will be forthcoming and the WHO will be able to determine whether the prevalence of MDR-TB is increasing.

A survey of TB drug resistance at the five largest TB treatment centers in Port-au-Prince was conducted to determine the prevalence rates of primary MDR-TB and to determine whether there has been an increase since 1990. A secondary objective of this study was to validate the use of molecular tests for the diagnosis of MDR-TB in Haiti before their clinical application.

**METHODS**

**Study design**

This was a cross-sectional prevalence study of *M. tuberculosis* drug resistance among patients presenting with new acid-fast bacillus smear-positive active pulmonary tuberculosis at the five largest TB treatment centers in the metropolitan Port-au-Prince area in 2008. Sputum samples were cultured from these five centers for *M. tuberculosis*. Isolates were then examined by sequence analysis of the *rpoB* gene, which is known to be associated with > 95% of rifampin resistance (12). *M. tuberculosis* isolates resistant to rifampin by *rpoB* DNA sequence analysis were sent to the Mycobacteriology Laboratory of the New York State Department of Health for drug susceptibility testing (DST). A subset of isolates negative for rifampin resistance by *rpoB* gene analysis was also sent to the New York reference laboratory. The prevalence of MDR isolates is reported, defined as isolates that were resistant to rifampin by *rpoB* gene analysis with confirmation of resistance to rifampin and isoniazid by DST at the New York reference laboratory.

**Study setting and population**

The five tuberculosis centers in Port-au-Prince and its environs included Grace Children’s Hospital, the Haitian State Sanatorium, GHESKIO Centers, Sigueneau Sanatorium, and the Menonite Mission of Croix des Bouquets. These centers cover about 75% of all TB cases treated in the Port-au-Prince area. The patients were consecutively diagnosed with an acid-fast bacillus-positive smear in 2008. They did not report a prior diagnosis of TB.

A laboratory technician placed a 2- to 5-mL aliquot of sputum from each patient into a 50-mL plastic tube. The tube was labeled with the patient’s age, gender, and HIV status (positive, negative, unknown). The sample was refrigerated at 4°C and transported within 2 days to a central laboratory at the GHESKIO Centers.

**Laboratory studies**

Sputum samples were decontaminated with sodium lauryl sulfate and cultured on Löwenstein-Jensen slants (Becton Dickenson, Franklin Lakes, New Jersey, United States of America). For positive cultures, a loopful of mycobacteria was resuspended in 300 µL of nuclease-free water, heat-killed by 20 min of incubation at 95°C, and disrupted by three cycles of freezing at −70°C and heating at 95°C. DNA was separated from debris using Spin-X centrifuge filter tubes, 0.22-µm pore size (COSTAR, Corning Inc., Lowell, Massachusetts, United States). The 329-bp *rpoB* fragment was amplified in 35 cycles of polymerase chain reaction (PCR). PCR parameters were 30 s of denaturation at 95°C, 1 min of annealing at 55°C, and 1 min of extension at 72°C. Each 50-µL reaction mixture consisted of 5 µL of DNA extract, 0.2 µM each primers *rpoB*-F (5’-CCA-CCC-AGG-AGG-TTG-AGG-GGA-TCA-CAC-3’) and *rpoB*-R (5’-CGT-TTC-GAT-GAA-CCC-AGG-AGG-GGA-TCA-CAC-3’), 200 mM dNTPs, and 1.25 units of Hot-Start Taq polymerase (QIAGEN, Hilden, Germany) in buffer provided with polymerase kit.

PCR fragments were purified with a QIAquick PCR purification kit (QIAGEN, Hilden, Germany), premixed with the primers used for PCR amplification, and sent for Sanger sequencing at Cornell University Bio Resource Center (Ithaca, New York, United States). The sequences obtained were compared with the wild-type *rpoB* sequence of H37Rv for *M. tuberculosis* complex identification and for detection of mutations. Isolates were provisionally classified as rifampin resistant if they had a polymorphism previously described as conferring resistance (12).

DNA extracts from all isolates were tested for mutations associated with resistance to isoniazid and rifampin by a commercially available line-probe assay according to the manufacturer’s instructions (GenoType MTBDRplus, Hain Life Sciences, Nehren, Germany). The operator performing the test was blinded to the results of *rpoB* sequence analysis.

All isolates with *rpoB* mutations, along with a subset of isolates without *rpoB* mutations, were sent to the Laboratory of Clinical Mycobacteriology, Wadsworth Center, New York State Department of Health (Albany, New York, United States). All specimens were confirmed as *M. tuberculosis* complex by real-time PCR assay (13). In New York, drug sensitivity testing to first-line antituberculosis drugs was performed in Mycobacteria growth indicator tubes (BACTEC 960, Becton Dickenson, Franklin Lakes, New Jersey, United States) in accordance with the manufacturer’s instructions. For isolates resistant to at least one first-line drug, DST to isoniazid, rifampin, ethambutol, streptomycin, capreomycin, cycloserine, ethionamide, kanamycin, p-aminosalicylic acid, amikacin, and ofloxacin was performed with the proportion method on 7H10 agar as recommended by the Clinical and Laboratory Standards Institute (14).

**Analysis**

The prevalence, with 95% confidence intervals, of MDR-TB at five major TB treatment centers around Port-au-Prince is reported. Proportions were compared using Fisher’s exact test and medians with the Wilcoxon rank sum test. This
study was approved by the Institutional Review Board at GHESKIO and Weill Cornell Medical College (New York).

RESULTS

Study population

The five sites sent sputum samples from 1,006 patients to the central laboratory at GHESKIO for analysis. Of them, 909 grew *Mycobacterium* on Lowenstein–Jensen media and yielded DNA extracts suitable for PCR sequencing. Of the 909 isolates, 906 belonged to the *M. tuberculosis* complex. The characteristics of the 906 patients from whom *M. tuberculosis* was isolated are presented in Table 1. The median age was 30 years, 49.1% were female, and 77.9% of patients were HIV-1 seronegative. Each site contributed approximately the same number of samples.

Prevalence of MDR-TB

The 81-bp core region of the *rpoB* gene was sequenced for all isolates. Of the 906 *M. tuberculosis* isolates, 27 (2.9%) contained missense mutations or deletions in the *rpoB* gene that are known to be associated with rifampin resistance. One additional isolate had a silent mutation or synonymous single nucleotide polymorphism in *rpoB* codon T508 (ACC → ACT) from 1,006 patients to the central laboratory at GHESKIO for analysis. Of them, 909 grew *Mycobacterium* on Lowenstein–Jensen media and yielded DNA extracts suitable for PCR sequencing. Of the 909 isolates, 906 belonged to the *M. tuberculosis* complex. The characteristics of the 906 patients from whom *M. tuberculosis* was isolated are presented in Table 1. The median age was 30 years, 49.1% were female, and 77.9% of patients were HIV-1 seronegative. Each site contributed approximately the same number of samples.

Prevalence of MDR-TB

The 81-bp core region of the *rpoB* gene was sequenced for all isolates. Of the 906 *M. tuberculosis* isolates, 27 (2.9%) contained missense mutations or deletions in the *rpoB* gene that are known to be associated with rifampin resistance. One additional isolate had a silent mutation or synonymous single nucleotide polymorphism in *rpoB* codon T508 (ACC → ACT).

<table>
<thead>
<tr>
<th>Site</th>
<th>No.</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site 1</td>
<td>226</td>
<td>24.9</td>
</tr>
<tr>
<td>Site 2</td>
<td>210</td>
<td>21.0</td>
</tr>
<tr>
<td>Site 3</td>
<td>202</td>
<td>20.1</td>
</tr>
<tr>
<td>Site 4</td>
<td>120</td>
<td>13.2</td>
</tr>
<tr>
<td>Site 5</td>
<td>188</td>
<td>20.7</td>
</tr>
</tbody>
</table>

Note: NA: not applicable.

* May not sum to 100 due to rounding.

The 27 *M. tuberculosis* isolates with missense mutations or deletions in *rpoB* were sent to the New York State TB Laboratory. Twenty-six isolates grew in New York, and one isolate was not viable upon subculture. All 26 isolates that grew in New York were confirmed as *M. tuberculosis*. All 26 isolates tested resistant to rifampin by conventional culture DST on solid and liquid media. All 26 were also resistant to isoniazid and hence were classified as MDR-TB. The complete drug sensitivity profile of the 26 MDR isolates is shown in Table 2.

In total, 26 of 906 (2.9%) *M. tuberculosis* isolates were confirmed to be MDR. No statistically significant associations were found between patient age, gender, or HIV status and multidrug resistance.

The one isolate that had a silent mutation or synonymous single nucleotide polymorphism in *rpoB* codon T508 (ACC → ACT) was also analyzed by DST in the reference laboratory and found to be sensitive to rifampin. An additional 46 isolates, which were negative for mutations in the core region of *rpoB*, were also sent to the New York State Laboratory for control DST. All 46 isolates were sensitive to rifampin.

Screening with GenoType MTBDRplus line-probe assay

A line-probe assay was performed on DNA extracts from the 906 *M. tuberculosis* isolates. The MTBDRplus assay identified 28 (3.1%) samples as resistant to rifampin. This number included all 27 isolates identified by sequencing as having a missense mutation or deletion in the *rpoB* gene and the one isolate that had a synonymous single nucleotide polymorphism in *rpoB* codon T508 (ACC → ACT).

The remaining isolates were sensitive to rifampin by the MTBDRplus assay.

DISCUSSION

This study documents that the rates of MDR-TB have increased in Haiti since studies in the 1990s showed that fewer than 1.0% of patients with newly diagnosed TB were resistant to isoniazid and rifampin (7, 8). Studies from the neighboring Dominican Republic, which shares the island of Hispaniola with Haiti, also have shown a high MDR-TB rate of 10.2% in all cases and 6.6% in new TB cases (11). Given the large amount of migration between countries throughout the Western Hemisphere, the results of these studies are of particular concern for the spread of previously localized disease.

The results of this study have become even more relevant since the 12 January 2010 earthquake, when the headquarters of the National TB Program and several large TB treatment centers were destroyed, including three of the five centers that participated in this study (15). Thousands of TB patients in Port-au-Prince defaulted on therapy and are now living in crowded tent cities. Rates of MDR-TB may climb even higher under these catastrophic conditions.

This study was limited in that gold-standard culture-based drug sensitivity testing was performed only on the samples that tested positive for *rpoB* mutations and only on a subset of the isolates that were negative for the *rpoB* mutations. Therefore, the prevalence of MDR-TB may be underestimated. However, all 46 isolates without *rpoB* mutations tested negative for rifampin resistance by a standard culture method, and other studies suggest a > 95.0% correlation between *rpoB* sequence analysis
and phenotypic drug sensitivity testing. Therefore, it is unlikely that the actual rates of MDR-TB are significantly higher than 3.0%.

At least 2.9% of patients newly diagnosed with smear-positive pulmonary tuberculosis in Port-au-Prince have MDR-TB. Sequencing or hybridization assays of the rpoB gene are good screening tools in this population for early detection and appropriate treatment of MDR-TB.

**REFERENCES**


**RESUMEN**

**Objetivo.** Determinar la prevalencia de tuberculosis (TB) multirresistente en pacientes con TB pulmonar nueva con baciloscopia positiva en Puerto Príncipe, Haití.

**Métodos.** Se cultivaron muestras de esputo de 1 006 pacientes con diagnóstico reciente de tuberculosis efectuado durante el 2008. Se secuenció la región nuclear del gen rpoB, que se asocia con la resistencia a la rifampicina. Todos los aislados con mutaciones de rpoB se enviaron al laboratorio de referencia del estado de Nueva York para llevar a cabo un antibiograma convencional. Todos los aislados se estudiaron también con el ensayo de sonda lineal GenoType MTBDRplus.

**Resultados.** Se aisló Mycobacterium tuberculosis de 906 pacientes. Veintiséis (2,9%) de los aislados presentaban mutaciones de sentido erróneo o delecciones en rpoB y fueron resistentes a la rifampicina en el antibiograma. Los 26 aislados fueron resistentes también a la isoniaciada y se clasificaron como TB multirresistente. Cuarenta y seis aislados de control sin mutaciones de rpoB resultaron sensibles a la rifampicina en el antibiograma. El ensayo de sonda lineal GenoType MTBDRplus identificó correctamente a las 26 cepas de TB multirresistente y clasificó de manera errónea un aislado sensible a múltiples fármacos como resistente a la rifampicina.

**Conclusiones.** Este estudio revela una prevalencia de TB multirresistente de 2,9% en los pacientes con TB recién diagnosticada en Haití e indica que los ensayos de secuenciación e hibridación de rpoB son estudios de detección sistemáticamente adecuados para la detección temprana de la TB multirresistente.

**Palabras clave** Tuberculosis resistente a múltiples medicamentos; estudios transversales; Haití.

224

Rev Panam Salud Publica 31(3), 2012